Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2012 1
2013 1
2019 1
2020 1
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of CD34+ cell mobilization, blood graft cellular composition, and post-transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low-dose cyclophosphamide: A prospective multicenter study.
Anu P, Antti T, Raija S, Marja P, Jaakko V, Timo S, Mervi P, Marja S, Anu S, Karri P, Taru K, Jukka P, Pentti M, Esa J, Ville V. Anu P, et al. Among authors: anu s. Transfusion. 2021 Nov;61(11):3202-3212. doi: 10.1111/trf.16645. Epub 2021 Sep 9. Transfusion. 2021. PMID: 34498764
Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
Turunen A, Silvennoinen R, Partanen A, Valtola J, Siitonen T, Putkonen M, Sankelo M, Pyörälä M, Kuittinen T, Penttilä K, Sikiö A, Savolainen ER, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Turunen A, et al. Among authors: sikio a. Transfusion. 2021 Jun;61(6):1830-1844. doi: 10.1111/trf.16424. Epub 2021 May 6. Transfusion. 2021. PMID: 33955591 Free article. Clinical Trial.
Teriparatide treatment complicated by malignant myeloma.
Koski AM, Sikiö A, Forslund T. Koski AM, et al. Among authors: sikio a. BMJ Case Rep. 2010 Aug 13;2010:bcr0120102681. doi: 10.1136/bcr.01.2010.2681. BMJ Case Rep. 2010. PMID: 22767690 Free PMC article.
Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.
Partanen A, Turunen A, Silvennoinen R, Valtola J, Pyörälä M, Siitonen T, Sikiö A, Putkonen M, Sankelo M, Penttilä K, Kuittinen T, Mäntymaa P, Pelkonen J, Jantunen E, Varmavuo V. Partanen A, et al. Among authors: sikio a. J Clin Apher. 2023 Feb;38(1):33-44. doi: 10.1002/jca.22022. Epub 2022 Oct 14. J Clin Apher. 2023. PMID: 36239392
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundán T, Juvonen V, Luukkaala T, Remes K. Silvennoinen R, et al. Among authors: sikio a. Br J Haematol. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4. Br J Haematol. 2013. PMID: 23206270 Free article. Clinical Trial. No abstract available.
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
Luoma S, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen T, Kakko S, Putkonen M, Ollikainen H, Terävä V, Sankelo M, Partanen A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Lievonen J, Selander T, Pelliniemi TT, Ilveskero S, Huotari V, Mäntymaa P, Tienhaara A, Jantunen E, Silvennoinen R. Luoma S, et al. Among authors: sikio a. Ann Hematol. 2019 Dec;98(12):2781-2792. doi: 10.1007/s00277-019-03815-7. Epub 2019 Oct 31. Ann Hematol. 2019. PMID: 31673775 Free PMC article. Clinical Trial.
CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.
Turunen A, Partanen A, Valtola J, Ropponen A, Siitonen T, Kuittinen O, Kuitunen H, Putkonen M, Sankelo M, Keskinen L, Savolainen ER, Pyörälä M, Kuittinen T, Silvennoinen R, Penttilä K, Sikiö A, Vasala K, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Turunen A, et al. Among authors: sikio a. Transfusion. 2020 Jul;60(7):1519-1528. doi: 10.1111/trf.15820. Epub 2020 Apr 24. Transfusion. 2020. PMID: 32333404 Free article. Clinical Trial.
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Säily M, Uttervall K, Putkonen M, Carlson K, Haukas E, Sankelo M, Szatkowski D, Hansson M, Marttila A, Svensson R, Axelsson P, Lauri B, Mikkola M, Karlsson C, Abelsson J, Ahlstrand E, Sikiö A, Klimkowska M, Matuzeviciene R, Fenstad MH, Ilveskero S, Pelliniemi TT, Nahi H, Silvennoinen R. Partanen A, et al. Among authors: sikio a. Cancers (Basel). 2024 Feb 29;16(5):1024. doi: 10.3390/cancers16051024. Cancers (Basel). 2024. PMID: 38473382 Free PMC article.